Overview
PRCT market data
Price History
PRCT price chart
Valuation & Profitability
No Valuation Data Yet
Alpha Vantage and Twelve Data both returned no valuation metrics for PRCT. Check back after the next daily valuation refresh — this symbol may be new, delisted, or temporarily unavailable from both providers.
Company news
Truist Securities Downgrades PROCEPT BioRobotics to Hold, Lowers Price Target to $25Benzinga · Jul 6, 2026, 11:30 AM
This Nucor Analyst Turns Bullish; Here Are Top 4 Upgrades For WednesdayBenzinga · Jun 24, 2026, 1:05 PM
This Take-Two Interactive Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For WednesdayBenzinga · Jun 24, 2026, 11:40 AM
This MarketAxess Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For ThursdayBenzinga · Jun 11, 2026, 3:42 PM
PROCEPT BioRobotics shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform rating and lowered its price target from $31 to $29.Benzinga · Jun 11, 2026, 2:37 PM
Leerink Partners Downgrades PROCEPT BioRobotics to Market Perform, Lowers Price Target to $29Benzinga · Jun 11, 2026, 2:33 PM
PROCEPT BioRobotics Announces Two Milestones In Its WATER IV Prostate Cancer Clinical ProgramBenzinga · May 28, 2026, 12:20 PM